Occupation or Discipline
FDA’s Rejection of Lykos’ MDMA-Assisted Therapy for PTSD: A Setback but Not a Roadblock for Psychedelic Research
MDMA, PTSD, Lykos Therapeutics, FDA rejection, psychedelic therapy, clinical trials, ethical violations, scientific integrity.
Evotec Announces 400 Job Cuts Amid Market Challenges
Evotec, job cuts, market challenges, restructuring, drug discovery, contract development, manufacturing
Biopharma Layoff Tracker 2024: FibroGen, Ajinomoto, AN2 Therapeutics and More Cut Staff
Biopharma layoffs, FibroGen, Ajinomoto, AN2 Therapeutics, pharmaceutical industry, job cuts, restructuring
Precigen Restructures, Reduces CAR-T Efforts Amid Job Cuts
Precigen, CAR-T, restructuring, job cuts, UltraCAR-T, gene therapy, AdenoVerse, PRGN-2012
Biopharma Layoff Tracker 2024: Precigen, Sumitomo, BMS and More Cut Staff
biopharma layoffs, Precigen, Sumitomo, Bristol Myers Squibb, biotech industry, job cuts, restructuring, pharmaceutical companies
Bayer’s Transformation Accelerates with 3,200 Job Cuts in 2024
Bayer, transformation, job cuts, 2024, Bill Anderson, pharmaceutical industry
Bayer Announces 3,200 Job Cuts, Highlights Progress in Pharmaceutical Pipeline
Bayer, job cuts, pharmaceutical pipeline, cost savings, organizational restructuring
Biopharma Layoff Tracker 2024: uniQure, Vir, Arbutus, and More Cut Staff
biopharma layoffs, uniQure, Vir, Arbutus, biotech industry, job cuts, restructuring initiatives
Biotech Startup Airna Secures $60M to Advance RNA-Editing Therapy for Alpha-1 Antitrypsin Deficiency
Airna, RNA editing, alpha-1 antitrypsin deficiency, AATD, biotech startup, genetic medicine, ADAR, CRISPR, RNA therapy
Biopharma Layoff Tracker 2024: FibroGen, Pfizer, Cue, and More Cut Staff
Biopharma layoffs, FibroGen, Pfizer, Cue, Anokion, biotech industry, job cuts, restructuring initiatives